1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>China

China Regulatory Overreach Prompts Concerns For FDA Inspections, Innovation

More Dial-Back to Come?

 
• By Brian Yang

As China prioritizes national security over economic development, a plethora of regulations could cause unintended consequences, including US FDA field inspections in the country.

REGULATION, LAW, RULE_742040296 _1200.jpg
some overreaching China biopharma regs seen discouraging innovation, prompting dial-back • Source: Shutterstock

China has in recent years issued a plethora of legislative and regulatory changes centered on improving national security, ranging from biosecurity measures to human genetic resource management to a sweeping anti-espionage law.

Coupled with what Western governments see as “arbitrary” regulatory practices, however, this has prompted concerns that overreach of the country's legal and regulatory systems may

Last August, a group of US Republican lawmakers sent a letter to US Food and Drug Administration Commissioner Robert Califf raising the issue of what they believed to be insufficient

More from China

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

China Plans Clinical Data Protection By Product Category For First Time

 
• By Xu Hu

After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.

China Approvals Rise But Conditional-To-Full Conversion Slips

 
• By Xu Hu

A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.

Elevar/Hengrui’s Second US CRL A Bad Omen For Multiregional Trials In Asia-Dominant Cancers?

 
• By Dexter Jie Yan

While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.

More from Asia

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.